Ascendis Pharma A (ASND) Consolidated Net Income (2014 - 2026)

Ascendis Pharma A has reported Consolidated Net Income for 13 years, with the latest figure at -$849.6 million in Q1 2026.

• Quarterly Consolidated Net Income fell 773.15% year-over-year to -$849.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$970.8 million (down 169.6% YoY) and the FY2025 annual result came in at -$293.7 million, up 25.38% from the prior year.
• Consolidated Net Income eased to -$849.6 million in Q1 2026 per ASND's latest filing, from -$23.1 million in the prior quarter.
• Over five years, Consolidated Net Income peaked at -$23.1 million in Q4 2025 and troughed at -$849.6 million in Q1 2026.
• A 5-year average of -$151.4 million and a median of -$116.3 million in 2023 frame the typical range for Consolidated Net Income.
• The sharpest annual moves came in 2025 and 2026: Consolidated Net Income soared 69.93% in 2025, then tumbled 773.15% in 2026.
• Over 5 years, Consolidated Net Income stood at -$200.7 million in 2022, then soared by 59.64% to -$81.0 million in 2023, then surged by 52.12% to -$38.8 million in 2024, then surged by 40.44% to -$23.1 million in 2025, then plunged by 3577.3% to -$849.6 million in 2026.
• According to Business Quant data, Consolidated Net Income over the past three periods registered -$849.6 million, -$23.1 million, and -$62.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.